Jefferies analyst Hisae Kawamoto upgraded Rohto Pharmaceutical (RPHCF) to Buy from Hold with a price target of 2,980 yen, up from 2,200 yen. The firm cites the strength of the company’s Asia business for the upgrade.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPHCF: